Stock Monitor: Albireo Pharma Post EarningsReporting

LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Trevena,Inc. (NASDAQ: TRVN), all you need to do is sign up now by clicking thefollowing link www.active-investors.com/registration-sg/?symbol=TRVN as the Company?s latest news hit the wire. OnMay 22, 2018, the Company, which is a biopharmaceutical organization developinginnovative therapies based on breakthrough science to benefit patients and healthcareproviders confronting serious medical conditions, announced that it showcasedtwo presentations at the American Society of Colon and Rectal Surgeons 2018Annual Scientific Meeting. The meeting is being held in Nashville, Tennesseefrom May 19 to May 23, 2018. Register today and get access to over 1,000Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the researchreport for Albireo Pharma, Inc. (NASDAQ: ALBO), which also belongs to the Healthcaresector as the Company Trevena. Do not miss out and become a member today forfree to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ALBO

Active-Investors.com is focused ongiving you timely information and the inside line on companies that matter toyou. This morning, Trevenamost recent newsis on our radar and our team decided toput out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=TRVN

E-poster Presentation (P499): Safetyof Oliceridine, a G Protein-Biased Ligand at the µ-Opioid Receptor, in Patientswith Moderate-to-Severe Acute Pain after Colorectal Surgery

Thisposter presentation showcased results from the ATHENA Phase-3 study ofTrevena?s investigational product, Oliceridine, on Tuesday, May 22, 2018, from12:00 ? 12:05 pm on Monitor #10 in the e-poster area of the Exhibit Hall in theMusic City Center.

Oliceridineis the next generation IV analgesic for the management of moderate-to-severeacute pain in the hospital and similar settings. Oliceridine aims to improveconventional opioid pharmacology by providing the pain-reducing potential of anopioid but with lesser adverse effects. So far, Oliceridine has not beenapproved by the US Food and Drug Administration (FDA) or any other regulatoryagency. However, the FDA granted the drug a Breakthrough Therapy designation onFebruary 22, 2016.

Theposter presentation portrayed the efficacy, safety, and tolerability data from115 colorectal patients from the ATHENA Phase-3 multicenter, open-label safetystudy. In this study, Oliceridine was administered to 768 patients withmoderate-to-severe acute pain caused by medical conditions or surgery. Thestudy intended to test real-world use of Oliceridine in a broad patient casemix, as well as representative surgeries in clinical practice at 41 sites inthe US. The trial also covered patients who were at increased risk foropioid-induced respiratory depression (OIRD), with 32% of patients aged 65years and above, and over 50% with a body mass index (BMI) greater than 30kg/m2. The trial results proved that Oliceridine can be easily substituted forconventional IV opioids to control moderate-to-severe acute pain.

AnthonySenagore, M.D., Professor of Surgery at Western Michigan University, HomerStryker School of Medicine, shared that pain management after colorectalsurgery represents an area of unmet medical need. Even after an extensive usageof multimodal analgesia, numerous patients still depend on IV morphine for painmanagement. As a result, they suffer from opioid-related adverse effects.Senagore believes that Oliceridine has the potential to replace conventional IVopioids.

E-poster presentation (P489):Prevalence and Burden of Opioid-Induced Respiratory Depression andPostoperative Nausea/Vomiting Associated with the Treatment of AcutePostoperative Pain Following General/Colorectal Surgery

Thisposter presentation was presented on Tuesday, May 22, 2018, from 12:20 - 12:25pm on Monitor #9 in the Exhibit Hall in the Music City Center. It portrayedtreatment patterns, burden, and predictors of post-operative nausea/vomitingand OIRD associated with the use of conventional IV opioids for controllingsevere postoperative pain in about 158,000 general and colorectal surgerypatients in the Premier Perspectives Hospital Database. The trial showed thatobesity, respiratory conditions, and sleep apnea were related to a greaterlikelihood of opioid-induced adverse events, and considerably higher totalhospital costs.

Stock Performance Snapshot

May23, 2018 - At Wednesday?s closing bell, Trevena?s stock was marginallyup 0.57%, ending the trading session at $1.75.

Volume traded for theday: 551.71 thousand shares.

Stock performance in thelast month ? up 3.55%; previous three-month period ? up 7.36%; past six-monthperiod ? up 0.57%; and year-to-date - up 9.37%

After yesterday?s close, Trevena?s market cap was at $119.61million.

The stock is part of the Healthcaresector, categorized under the Biotechnology industry. This sector was up 0.2%at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors